Latest forecast sees obesity market reaching $173.5 billion sales in 7MM
The number of patients living with obesity keeps growing, and following the recent advances in the therapeutic space, more patients are being prescribed pharmacotherapy on top of the usual diet and exercise lifestyle changes, which by themselves are often unsuccessful.
With physicians and patients awareness expected to increase, sales of obesity medications are forecast to reach $173.5 billion in the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) by 2031.
Pharma analytics company GlobalData’s latest report “Obesity: Seven-Market Drug Forecast and Market Analysis- Update” reveals that the revolution in obesity treatment is not over yet, and many changes are still needed to fulfill the unmet needs in the obesity space.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze